Roy Buchanan

Sudan Loganathan

Jay Olson

Liang Cheng

Yi Chen

Gregory Renza

Anish Nikhanj

Cheng Li

Eduardo Martinez-Montes

Edward Tenthoff

Roger Song

- INOVIO has begun the rolling submission of its Biologics License Application (BLA) for **INO-3107**, a treatment for **Recurrent Respiratory Papillomatosis (RRP)** in adults, with the FDA agreeing to the timeline.  **[1055726_20250826PH58699:0]** 
- The company aims to complete the BLA submission in the coming months and seeks **priority review**, targeting FDA file acceptance by the **end of 2025**.  **[1055726_20250826PH58699:0]** 
- **INO-3107** holds **Orphan Drug** and **Breakthrough Therapy** designations from the FDA, enabling submission under the accelerated approval program based on Phase 1/2 trial data.  **[1055726_20250826PH58699:1]** 
- In the Phase 1/2 trial, **72%** of patients saw a **50-to-100% reduction** in surgeries after one year, increasing to **86%** after two years for a subset of participants, with **half** of those requiring no surgeries.  **[1055726_20250826PH58699:1]**

Inovio begins rolling BLA submission for INO-3107

INOVIO PHARMACEUTICALS (INO)